Alex Leech was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and was CEO of Zarodex Therapeutics and Camphos Therapeutics. Prior to Creabilis, he led operations at US-based pain company Solace Pharmaceuticals Inc. Alex gained his R&D experience at Pfizer and is a former Venture Partner with SV Health Investors.
